JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Song, Z.-H.
Right arrow Articles by Slowey, C.-A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, Z.-H.
Right arrow Articles by Slowey, C.-A.

Vol. 292, Issue 1, 136-139, January 2000

Involvement of Cannabinoid Receptors in the Intraocular Pressure-Lowering Effects of WIN55212-21

Zhao-Hui Song and Carole-Anne Slowey

Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky (Z.H.S.); and Department of Medical Pharmacology and Toxicology, Texas A&M University Health Science Center, College Station, Texas (Z.H.S., C.-A.S.)

It is known that marijuana smoking and administration of natural cannabinoids reduce intraocular pressure. However, it has not been established whether the intraocular pressure-lowering effects of cannabinoids are mediated by cannabinoid receptors. Aminoalkylindoles are a new class of cannabimimetics with structures entirely different from those of natural cannabinoids. WIN55212-2, a prototypic aminoalkylindole, has been shown to bind cannabinoid receptors and to exhibit cannabinoid-like activities. The objective of this study was to determine whether aminoalkylindoles lower intraocular pressure and whether the effects of aminoalkylindoles are mediated by ocular cannabinoid receptors. The intraocular pressure of New Zealand White rabbits was measured with the use of applanation pneumatonography. After the measurement of baseline intraocular pressure, drugs were applied topically and the intraocular pressure was monitored. The topical application of WIN55212-2 significantly reduced intraocular pressure in the treated eyes. The intraocular pressure-lowering effects of WIN55212-2 were time and dose dependent, and the maximal reduction was 4.7 ± 0.5 mm Hg at a dose of 100 µg. In contrast to treated eyes, the intraocular pressure on the contralateral eyes was not significantly affected. The topical application of WIN55212-3, the enantiomer of WIN55212-2, had no effect on intraocular pressure. Furthermore, the intraocular pressure-lowering effects of WIN55212-2 were significantly reduced by topically administered SR141716A, a selective antagonist for the CB1 cannabinoid receptor. The dose-response curve of WIN55212-2 is shifted parallel to the right by SR141716A. These data demonstrate that like natural cannabinoids, WIN55212-2 also reduces intraocular pressure, and the effects of WIN55212-2 are mediated at least in part by the CB1 cannabinoid receptors in the eye.

1 This work is supported in part by grants from the National Institute of Drug Abuse and Pharmaceutical Research and Manufacturers of America Foundation.

0022-3565/0/2921-0136$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 IOVSHome page
Y. F. Njie, Z. Qiao, Z. Xiao, W. Wang, and Z.-H. Song
N-arachidonylethanolamide-Induced Increase in Aqueous Humor Outflow Facility
Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4528 - 4534.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C. Addy, P. Rothenberg, S. Li, A. Majumdar, N. Agrawal, H. Li, L. Zhong, J. Yuan, A. Maes, S. Dunbar, et al.
Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers
J. Clin. Pharmacol., June 1, 2008; 48(6): 734 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. F. Njie, A. Kumar, Z. Qiao, L. Zhong, and Z.-H. Song
Noladin Ether Acts on Trabecular Meshwork Cannabinoid (CB1) Receptors to Enhance Aqueous Humor Outflow Facility
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1999 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Rosch, R. Ramer, K. Brune, and B. Hinz
R(+)-Methanandamide and Other Cannabinoids Induce the Expression of Cyclooxygenase-2 and Matrix Metalloproteinases in Human Nonpigmented Ciliary Epithelial Cells
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1219 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. Zhong, L. Geng, Y. Njie, W. Feng, and Z.-H. Song
CB2 Cannabinoid Receptors in Trabecular Meshwork Cells Mediate JWH015-Induced Enhancement of Aqueous Humor Outflow Facility
Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 1988 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
I Tomida, R G Pertwee, and A Azuara-Blanco
Cannabinoids and glaucoma
Br. J. Ophthalmol., May 1, 2004; 88(5): 708 - 713.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. B. El-Remessy, I. E. Khalil, S. Matragoon, G. Abou-Mohamed, N.-J. Tsai, P. Roon, R. B. Caldwell, R. W. Caldwell, K. Green, and G. I. Liou
Neuroprotective Effect of(-){Delta}9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-D-Aspartate-Induced Retinal Neurotoxicity: Involvement of Peroxynitrite
Am. J. Pathol., November 1, 2003; 163(5): 1997 - 2008.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
F. Y. Chien, R.-F. Wang, T. W. Mittag, and S. M. Podos
Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in Monkeys
Arch Ophthalmol, January 1, 2003; 121(1): 87 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Zhang, P. Ma, M. Iszard, R. B. Cole, W. Wang, and G. Wang
In Vitro Metabolism of R(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a Cannabinoid Receptor Agonist
Drug Metab. Dispos., October 1, 2002; 30(10): 1077 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Laine, K. Jarvinen, R. Mechoulam, A. Breuer, and T. Jarvinen
Comparison of the Enzymatic Stability and Intraocular Pressure Effects of 2-Arachidonylglycerol and Noladin Ether, a Novel Putative Endocannabinoid
Invest. Ophthalmol. Vis. Sci., October 1, 2002; 43(10): 3216 - 3222.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Laine, K. Jarvinen, D. W. Pate, A. Urtti, and T. Jarvinen
Effect of the Enzyme Inhibitor, Phenylmethylsulfonyl Fluoride, on the IOP Profiles of Topical Anandamides
Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 393 - 397.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.